INTRODUCTION: Poor adherence to oral antipsychotic (OAP) therapy is a major driver of relapse in patients with schizophrenia, as only 50% or fewer patients are adherent to OAP during the first year, leading to suboptimal clinical outcomes and substantial healthcare costs.
